Ultram Generic Approval For Acute Pain Would Avoid Protected Label – Teva
Executive Summary
Teva is seeking approval for a generic version of Johnson & Johnson's Ultram (tramadol) only for acute pain in order to circumvent the brand's patent-protected titration schedule
You may also be interested in...
36Ultram Generics Will Reference 50 mg, But Not 25 Mg, Titration Schedule
FDA is approving Ultram (tramadol) generics with labeling that includes the 50 mg titration regimen, but not the protected 25 mg titration schedule
36Ultram Generics Will Reference 50 mg, But Not 25 Mg, Titration Schedule
FDA is approving Ultram (tramadol) generics with labeling that includes the 50 mg titration regimen, but not the protected 25 mg titration schedule
Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva
The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA